Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study - Summary - MDSpire

Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study

  • By

  • Yi Zhang

  • Hu Zhou

  • Shanshan Suo

  • Junling Zhuang

  • Linhua Yang

  • Aili He

  • Qingchi Liu

  • Xin Du

  • Sujun Gao

  • Yarong Li

  • Yan Li

  • Yuqing Chen

  • Wen Wu

  • Huanling Zhu

  • Guangsheng He

  • Mei Hong

  • Qian Jiang

  • Zhongxing Jiang

  • Hongmei Jing

  • Jishi Wang

  • Na Xu

  • Lingling Yue

  • Cuiping Zheng

  • Zeping Zhou

  • Chenghao Jin

  • Xin Li

  • Lin Liu

  • Yajing Xu

  • Dengshu Wu

  • Feng Zhang

  • Jin Zhang

  • Liqing Wu

  • Hewen Yin

  • Binhua Lv

  • Zhijian Xiao

  • Jie Jin

  • December 18, 2024

  • 0 min

Share

Objective:

To evaluate the efficacy and safety of gecacitinib compared to hydroxyurea in JAK inhibitor-naïve patients with intermediate-2 or high-risk myelofibrosis, focusing on primary endpoints such as spleen size reduction and quality of life improvements.

Key Findings:
  • Gecacitinib demonstrated superior efficacy in reducing spleen size compared to hydroxyurea.
  • Gecacitinib showed favorable safety and tolerability profiles.
  • Potential improvements in patients' quality of life were observed with gecacitinib treatment, including specific symptom relief.
Interpretation:

The results suggest that gecacitinib may be a more effective treatment option for managing myelofibrosis symptoms, including anemia, compared to hydroxyurea.

Limitations:
  • The study was limited to a specific population in China, which may affect generalizability.
  • Short follow-up duration may not capture long-term outcomes, and potential biases due to study design should be considered.
Conclusion:

Gecacitinib is a promising treatment for intermediate-2 or high-risk myelofibrosis, offering better efficacy and safety compared to hydroxyurea, warranting further studies to confirm these findings.

Original Source(s)

Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study

  • by Yi Zhang, Hu Zhou, Shanshan Suo, Junling Zhuang, Linhua Yang, Aili He, Qingchi Liu, Xin Du, Sujun Gao, Yarong Li, Yan Li, Yuqing Chen, Wen Wu, Huanling Zhu, Guangsheng He, Mei Hong, Qian Jiang, Zhongxing Jiang, Hongmei Jing, Jishi Wang, Na Xu, Lingling Yue, Cuiping Zheng, Zeping Zhou, Chenghao Jin, Xin Li, Lin Liu, Yajing Xu, Dengshu Wu, Feng Zhang, Jin Zhang, Liqing Wu, Hewen Yin, Binhua Lv, Zhijian Xiao, Jie Jin

  • December 18, 2024

Related Content

Evaluation of Serum Biomarkers to Inform Anemia Management in Individuals with Chronic Liver Disease

Case Study: Two Instances of Idiopathic Plasmacytic Lymphadenopathy, a Subtype of Idiopathic Multicentric Castleman Disease, Accompanied by Xanthelasma Palpebrum from a Canadian Institution

Early detection and correction of preoperative anemia in patients undergoing colorectal surgery—a prospective study